Wockhardt To Export 100 Million Sputnik Vaccines
News Comes Following Respectable Q3 Results For Indian Pharma Firm
Executive Summary
Indian pharmaceutical firm Wockhardt is set to export up to 100 million doses of the Russian COVID-19 vaccine Sputnik V, through a technology transfer agreement with the Gamaleya National Research Institute of Epidemiology and Microbiology.
You may also be interested in...
Wockhardt Expands UK Vaccines Unit With Serum Institute Deal
India’s Wockhardt has announced a fresh collaboration with the Serum Institute of India that will see the firm create a new sterile fill-and-finish facility in the UK, as part of plans to deliver an additional 150 million vaccine doses.
Sputnik COVID-19 Vaccine Caught Up In Sanctions On Russia Over Ukraine Invasion
As Russia intensifies its invasion of Ukraine with missile attacks and a convoy of armored vehicles, the funder and promoter of the country’s COVID-19 vaccine, Sputnik V, has found itself the subject of punitive international sanctions alongside Russia’s Central Bank.
US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings
The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines.